



DR-TB STAT Update March 2018

Program numbers reported February 20, 2018

*Some country data only through December 31, 2017

Cumulative Program Numbers for BDQ, DLM, and the Shorter Regimen:

Country	BDQ	DLM	STR
Afghanistan	1	9	23
Armenia	122	60	-
Bangladesh	156	96	1686
Belarus	507	107	0
Botswana	2	0	0
Brazil	0	0	0
Cambodia	2	0	-
China	0	0	0
Democratic Republic of Congo	37	0	1168
Dominican Republic	4	3	-
Estonia	25	19	2
Ethiopia	73	46	0
Georgia	374	189	0
Haiti	22	6	0
India	881	81	0
Indonesia	191	0	239
Kazakhstan	298	157	0
Kenya	14	6	165
Kyrgyzstan	162	5	131
Latvia	72	53	0
Lesotho	73	113	0
Liberia	2	0	10
Mexico	0	0	0
Morocco	0	0	0
Mozambique	31	6	92
Myanmar	27	22	15
Namibia	36	2	3
Niger	11	0	330
Nigeria	8	0	83
North Korea	22	0	0
Pakistan	239	148	22
Papua New Guinea	42	0	11
Peru	170	4	0

Philippines	149	1	2569
Russia	1444	31	0
Somalia	0	0	0
South Africa	10429	125	3150
Swaziland	237	32	190
Tajikistan	97	23	89
Tanzania	4	0	0
Thailand	29	0	25
Uganda	27	0	0
Ukraine	63	0	0
Uzbekistan	268	0	155
Vietnam	104	0	184
Zambia	0	0	46
			796 (Ahmad et al, 2017)
			1006 (Trebucq et al, 2018)
Totals	16,455	1,344	12,190

***includes the observational cohorts from two meta-analyses papers since most of these individuals were treated as part of operational research projects under program conditions**


GDF Orders:

BDQ orders from GDF: 21404

DLM orders from GDF: 4920


Graphs

Cumulative Delamanid and Bedaquiline Use Over Time



**adjusted to exclude compassionate use of DLM in Nov 2016*

Cumulative Delamanid and Bedaquiline Use Over Time Compared with Conservative Estimated Need



**calculation of global estimated need for new drugs adjusted in 2016 based on the WHO Report and in 2017 based on cumulative number of patients needing new drugs*